Soligenix, Inc. (SNGX) 10-Year Financial Performance & Capital Metrics

SNGX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Show more

Revenue $0
EBITDA -$9M -22.7%
Net Income -$8M -34.6%
EPS (Diluted) -4.98 +60.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -248.97% +99.0%
ROIC -
Debt/Equity 0.36 -74.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-51.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM59.81%

ROCE

10Y Avg-276.99%

5Y Avg-362.28%

3Y Avg-497.29%

Latest-243.18%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.77M	10.45M	5.43M	5.24M	3.22M	1.93M	33.35K	250K	0	0
Revenue Growth %	0.24%	0.19%	-0.48%	-0.04%	-0.39%	-0.4%	-0.98%	6.5%	-1%	-
Cost of Goods Sold+	6.88M	8.43M	4.31M	4.6M	3.57M	1.82M	728.64K	550.82K	742.05K	119.37K
COGS % of Revenue	0.78%	0.81%	0.79%	0.88%	1.11%	0.94%	21.85%	2.2%	-	-
Gross Profit+	1.89M	2.02M	1.12M	643.73K	-351.78K	109.58K	-695.29K	-300.82K	-742.05K	-119.37K
Gross Margin %	0.22%	0.19%	0.21%	0.12%	-0.11%	0.06%	-20.85%	-1.2%	-	-
Gross Profit Growth %	0.09%	0.07%	-0.44%	-0.43%	-1.55%	1.31%	-7.34%	0.57%	-1.47%	0.84%
Operating Expenses+	9M	7.72M	8.03M	8.43M	10.19M	18.7M	12.4M	13.94M	6.96M	9.32M
OpEx % of Revenue	1.03%	0.74%	1.48%	1.61%	3.17%	9.68%	371.91%	55.75%	-	-
Selling, General & Admin	3.6M	3.43M	3.21M	2.95M	3.48M	4.33M	5.01M	6.69M	4.48M	4.22M
SG&A % of Revenue	0.41%	0.33%	0.59%	0.56%	1.08%	2.24%	150.18%	26.77%	-	-
Research & Development	5.4M	4.3M	5.51M	6.75M	8.12M	14.8M	8.19M	7.94M	3.31M	5.22M
R&D % of Revenue	0.62%	0.41%	1.01%	1.29%	2.53%	7.66%	245.45%	31.78%	-	-
Other Operating Expenses	0	0	-683K	-1.28M	-1.41M	-428.91K	-790.92K	-698.91K	-839.36K	-119.37K
Operating Income+	-7.11M	-5.71M	-7.59M	-9.06M	-10.54M	-18.59M	-13.1M	-14.24M	-7.7M	-9.44M
Operating Margin %	-0.81%	-0.55%	-1.4%	-1.73%	-3.28%	-9.63%	-392.76%	-56.96%	-	-
Operating Income Growth %	0.34%	0.2%	-0.33%	-0.19%	-0.16%	-0.76%	0.3%	-0.09%	0.46%	-0.23%
EBITDA+	-6.86M	-5.62M	-7.53M	-9.01M	-10.49M	-18.52M	-13.06M	-14.21M	-7.69M	-9.43M
EBITDA Margin %	-0.78%	-0.54%	-1.39%	-1.72%	-3.26%	-9.6%	-391.74%	-56.86%	-	-
EBITDA Growth %	0.35%	0.18%	-0.34%	-0.2%	-0.16%	-0.77%	0.29%	-0.09%	0.46%	-0.23%
D&A (Non-Cash Add-back)	247.46K	89.93K	68.56K	44.06K	54.45K	62.37K	34.16K	24.56K	6.55K	5.81K
EBIT	-7.11M	-5.71M	-7.59M	-9.06M	-10.11M	-18.51M	-12.51M	-14.13M	-7.67M	-9.46M
Net Interest Income+	-8.02K	2.22K	29.91K	158.57K	148.97K	-10.88K	-904.5K	-822.61K	-49.13K	213.97K
Interest Income	0	2.22K	29.91K	159.01K	148.97K	0	0	0	0	213.97K
Interest Expense	8.02K	0	0	0	0	10.88K	904.5K	822.61K	49.13K	0
Other Income/Expense	-1.21M	1.93M	29.91K	159.01K	574.75K	61.09K	-316.75K	-714.37K	-210.59K	763.81K
Pretax Income+	-8.32M	-3.78M	-7.56M	-8.9M	-9.97M	-18.53M	-13.42M	-14.95M	-7.91M	-8.68M
Pretax Margin %	-0.95%	-0.36%	-1.39%	-1.7%	-3.1%	-9.6%	-402.26%	-59.81%	-	-
Income Tax+	-489K	-530K	-417K	0	-610.68K	-836.89K	-864.74K	-1.15M	-1.77M	-409.11K
Effective Tax Rate %	0.94%	0.86%	0.94%	1%	0.94%	0.95%	0.94%	0.92%	0.78%	0.95%
Net Income+	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Net Margin %	-0.89%	-0.31%	-1.32%	-1.7%	-2.91%	-9.16%	-376.33%	-55.19%	-	-
Net Income Growth %	-0.17%	0.59%	-1.2%	-0.25%	-0.05%	-0.89%	0.29%	-0.1%	0.55%	-0.35%
Net Income (Continuing)	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-721.04	-321.60	-278.40	-162.09	-115.88	-154.45	-75.06	-76.89	-12.66	-4.98
EPS Growth %	-0.01%	0.55%	0.13%	0.42%	0.29%	-0.33%	0.51%	-0.02%	0.84%	0.61%
EPS (Basic)	-721.04	-223.20	-278.40	-162.09	-115.88	-154.45	-67.54	-76.96	-12.66	-4.98
Diluted Shares Outstanding	10.86K	14.93K	25.6K	54.91K	80.73K	114.53K	185.8K	179.46K	484.88K	1.66M
Basic Shares Outstanding	10.86K	14.51K	25.6K	54.91K	80.73K	114.53K	185.8K	179.29K	484.88K	1.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.15M	10.11M	9.42M	10.34M	7.49M	19.47M	26.57M	13.85M	9.51M	8.83M
Cash & Short-Term Investments	4.92M	8.77M	7.81M	8.98M	5.42M	18.68M	26.04M	13.36M	8.45M	7.82M
Cash Only	4.92M	8.77M	7.81M	8.98M	5.42M	18.68M	26.04M	13.36M	8.45M	7.82M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.99M	1.21M	1.34M	1.2M	1.46M	564.87K	242.72K	219.33K	195.15K	0
Days Sales Outstanding	82.64	42.15	90.25	83.69	166.05	106.8	2.66K	320.22	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	274.21K	866.01K	1.01M
Total Non-Current Assets+	236.1K	153.33K	133.85K	148.99K	282.04K	424.23K	300.41K	426.56K	290.01K	137.85K
Property, Plant & Equipment	47.37K	26.7K	37.16K	19.63K	161.5K	251.54K	128.38K	359.47K	241.76K	115.08K
Fixed Asset Turnover	185.11x	391.32x	146.17x	266.93x	19.91x	7.67x	0.26x	0.70x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	188.73K	126.63K	73.95K	46.86K	19.7K	23.25K	0	0	0	0
Long-Term Investments	0	0	0	0	0	73.14K	0	0	0	0
Other Non-Current Assets	0	0	22.73K	82.5K	100.83K	172.69K	172.03K	67.1K	48.24K	22.78K
Total Assets+	7.39M	10.27M	9.55M	10.49M	7.78M	19.89M	26.87M	14.28M	9.8M	8.97M
Asset Turnover	1.19x	1.02x	0.57x	0.50x	0.41x	0.10x	0.00x	0.02x	-	-
Asset Growth %	0.06%	0.39%	-0.07%	0.1%	-0.26%	1.56%	0.35%	-0.47%	-0.31%	-0.08%
Total Current Liabilities+	7.41M	2.87M	3.23M	4.21M	6.31M	6.08M	6.29M	16.52M	6.15M	4.85M
Accounts Payable	2.87M	1.71M	1.75M	2.13M	2.74M	2.13M	2.93M	3.87M	1.11M	667.9K
Days Payables Outstanding	152.18	73.92	148.51	168.78	279.88	426.92	1.47K	2.56K	546.59	2.04K
Short-Term Debt	292.72K	0	0	0	0	324.98K	0	9.9M	2.25M	1.37M
Deferred Revenue (Current)	298.68K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.43M	0	0	0	298.17K	0	302.94K	336.69K	2.42M	336.44K
Current Ratio	0.97x	3.52x	2.92x	2.46x	1.19x	3.20x	4.22x	0.84x	1.55x	1.82x
Quick Ratio	0.97x	3.52x	2.92x	2.46x	1.19x	3.20x	4.22x	0.84x	1.55x	1.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	6.15K	10.07M	9.86M	233.67K	1.12M	0
Long-Term Debt	0	0	0	0	0	9.95M	9.86M	0	1.01M	0
Capital Lease Obligations	0	0	0	0	6.15K	116.3K	0	233.63K	111.86K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	43	0	0
Total Liabilities	7.41M	2.87M	3.23M	4.21M	6.32M	16.15M	16.15M	16.75M	7.27M	4.85M
Total Debt+	292.72K	0	0	0	127.22K	10.51M	9.96M	10.24M	3.49M	1.48M
Net Debt	-4.63M	-8.77M	-7.81M	-8.98M	-5.29M	-8.17M	-16.08M	-3.12M	-4.95M	-6.33M
Debt / Equity	-	-	-	-	0.09x	2.81x	0.93x	-	1.39x	0.36x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-886.87x	-	-	-	-	-1708.00x	-14.48x	-17.31x	-156.69x	-
Total Equity+	-18.31K	7.4M	6.32M	6.28M	1.46M	3.74M	10.72M	-2.47M	2.52M	4.12M
Equity Growth %	0.88%	405.02%	-0.15%	-0.01%	-0.77%	1.57%	1.87%	-1.23%	2.02%	0.63%
Book Value per Share	-1.69	495.40	246.85	114.37	18.05	32.67	57.71	-13.77	5.20	2.48
Total Shareholders' Equity	-18.31K	7.4M	6.32M	6.28M	1.46M	3.74M	10.72M	-2.47M	2.52M	4.12M
Common Stock	31.27K	5.47K	8.73K	17.68K	21.75K	30.64K	2.86K	2.91K	10.38K	2.51K
Retained Earnings	-146.88M	-150.12M	-157.27M	-166.17M	-175.53M	-193.21M	-205.77M	-219.56M	-225.7M	-233.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-3.67K	-45.01K	-24.34K	41.94K	24.75K	22.24K	45.79K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.39M	-4.98M	-6.51M	-7.24M	-7.51M	-11.45M	-11.74M	-12.65M	-8.6M	-8.4M
Operating CF Margin %	-0.61%	-0.48%	-1.2%	-1.38%	-2.34%	-5.93%	-352%	-50.6%	-	-
Operating CF Growth %	-1.18%	0.07%	-0.31%	-0.11%	-0.04%	-0.53%	-0.02%	-0.08%	0.32%	0.02%
Net Income	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Depreciation & Amortization	247.46K	89.93K	68.56K	44.06K	54.45K	62.37K	34.16K	24.56K	6.55K	5.81K
Stock-Based Compensation	886.69K	574.98K	489.79K	380.89K	376.34K	409.93K	361.56K	333.39K	370.18K	329.81K
Deferred Taxes	315.18K	-383.32K	0	0	-3.84K	0	-421.58K	0	0	0
Other Non-Cash Items	897.34K	-1.49M	5.92K	1.48K	282.35K	5.25M	185.72K	366.25K	597.4K	-124.26K
Working Capital Changes	98.25K	-529.88K	72.24K	1.23M	1.14M	509.31K	651.5K	425.11K	-3.44M	-348.41K
Change in Receivables	-1.19M	778.43K	280.53K	-275.46K	182.88K	815.06K	64.89K	23.76K	33.89K	219.9K
Change in Inventory	0	0	0	0	-1.97M	1.16M	-1.13M	0	0	0
Change in Payables	1.38M	-1.48M	382.71K	1.02M	1.97M	-1.16M	1.13M	396.65K	-2.69M	-492.61K
Cash from Investing+	-22.1K	-7.16K	-26.35K	-925	-24.71K	-7.15K	-11.79K	-13.07K	0	0
Capital Expenditures	-22.1K	-7.16K	-26.35K	-1.93K	-30.21K	-7.15K	-11.79K	-13.07K	0	0
CapEx % of Revenue	0%	0%	0%	0%	0.01%	0%	0.35%	0.05%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1K	5.5K	0	0	0	0	0
Cash from Financing+	4.8M	8.84M	5.57M	8.42M	4.01M	24.68M	19.06M	76.82K	3.66M	7.76M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	965.68K	-850.66K	-672.36K	-251.89K	-130.2K	68.17K	-641.5K	-2.53K	-923.77K	3.32M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.41M	-4.99M	-6.54M	-7.25M	-7.54M	-11.46M	-11.75M	-12.66M	-8.6M	-8.4M
FCF Margin %	-0.62%	-0.48%	-1.2%	-1.38%	-2.34%	-5.94%	-352.36%	-50.65%	-	-
FCF Growth %	-1.15%	0.08%	-0.31%	-0.11%	-0.04%	-0.52%	-0.03%	-0.08%	0.32%	0.02%
FCF per Share	-497.97	-334.15	-255.34	-131.97	-93.39	-100.08	-63.25	-70.56	-17.74	-5.06
FCF Conversion (FCF/Net Income)	0.69x	1.54x	0.91x	0.81x	0.80x	0.65x	0.94x	0.92x	1.40x	1.02x
Interest Paid	0	0	0	0	0	34.41K	668.72K	857.41K	552.06K	227.74K
Taxes Paid	7.54K	5.03K	-5.08K	2.58K	11.13K	4.02K	7.73K	16.04K	20.73K	42.16K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-87.95%	-104.21%	-141.27%	-241.83%	-680.46%	-173.54%	-334.43%	-23803.12%	-248.97%
Gross Margin	21.51%	19.28%	20.66%	12.28%	-10.94%	5.68%	-2084.76%	-120.33%	-	-
Net Margin	-89.31%	-31.06%	-131.57%	-169.81%	-290.94%	-916.25%	-37632.97%	-5519.34%	-	-
Debt / Equity	-	-	-	-	0.09x	2.81x	0.93x	-	1.39x	0.36x
Interest Coverage	-886.87x	-	-	-	-	-1708.00x	-14.48x	-17.31x	-156.69x	-
FCF Conversion	0.69x	1.54x	0.91x	0.81x	0.80x	0.65x	0.94x	0.92x	1.40x	1.02x
Revenue Growth	24.49%	19.17%	-48.01%	-3.52%	-38.64%	-39.96%	-98.27%	649.6%	-100%	-

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Grant revenue	-	-	-	-	-	-	-	-	-	119.37K
Grant revenue Growth	-	-	-	-	-	-	-	-	-	-
CiVax	-	-	-	-	-	-	1.5M	1.5M	1.5M	-
CiVax Growth	-	-	-	-	-	-	-	0.00%	0.00%	-
Contract revenue	-	-	-	-	-	-	700K	600K	-	-
Contract revenue Growth	-	-	-	-	-	-	-	-14.29%	-	-
VaccinesBioDefenseMember	-	-	-	-	-	2.24M	-	-	-	-
VaccinesBioDefenseMember Growth	-	-	-	-	-	-	-	-	-	-
BioTherapeuticsMember	-	-	-	-	-	117.37K	-	-	-	-
BioTherapeuticsMember Growth	-	-	-	-	-	-	-	-	-	-
Vaccines Bio Defense	8.75M	10.45M	4.75M	4.16M	3.4M	-	-	-	-	-
Vaccines Bio Defense Growth	-	19.35%	-54.55%	-12.48%	-18.15%	-	-	-	-	-
Bio Therapeutics	13.97K	-	683.18K	1.08M	1.23M	-	-	-	-	-
Bio Therapeutics Growth	-	-	-	58.79%	13.19%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Soligenix, Inc. (SNGX) grew revenue by 0.0% over the past year. Growth has been modest.

Soligenix, Inc. (SNGX) reported a net loss of $10.6M for fiscal year 2024.

Dividend & Returns

Soligenix, Inc. (SNGX) has a return on equity (ROE) of -249.0%. Negative ROE indicates the company is unprofitable.

Soligenix, Inc. (SNGX) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Soligenix, Inc. (SNGX) 10-Year Financial Performance & Capital Metrics

SNGX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$9M -22.7%
Net Income -$8M -34.6%
EPS (Diluted) -4.98 +60.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -248.97% +99.0%
ROIC -
Debt/Equity 0.36 -74.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-51.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM59.81%

ROCE

10Y Avg-276.99%

5Y Avg-362.28%

3Y Avg-497.29%

Latest-243.18%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	8.77M	10.45M	5.43M	5.24M	3.22M	1.93M	33.35K	250K	0	0
Revenue Growth %	0.24%	0.19%	-0.48%	-0.04%	-0.39%	-0.4%	-0.98%	6.5%	-1%	-
Cost of Goods Sold+	6.88M	8.43M	4.31M	4.6M	3.57M	1.82M	728.64K	550.82K	742.05K	119.37K
COGS % of Revenue	0.78%	0.81%	0.79%	0.88%	1.11%	0.94%	21.85%	2.2%	-	-
Gross Profit+	1.89M	2.02M	1.12M	643.73K	-351.78K	109.58K	-695.29K	-300.82K	-742.05K	-119.37K
Gross Margin %	0.22%	0.19%	0.21%	0.12%	-0.11%	0.06%	-20.85%	-1.2%	-	-
Gross Profit Growth %	0.09%	0.07%	-0.44%	-0.43%	-1.55%	1.31%	-7.34%	0.57%	-1.47%	0.84%
Operating Expenses+	9M	7.72M	8.03M	8.43M	10.19M	18.7M	12.4M	13.94M	6.96M	9.32M
OpEx % of Revenue	1.03%	0.74%	1.48%	1.61%	3.17%	9.68%	371.91%	55.75%	-	-
Selling, General & Admin	3.6M	3.43M	3.21M	2.95M	3.48M	4.33M	5.01M	6.69M	4.48M	4.22M
SG&A % of Revenue	0.41%	0.33%	0.59%	0.56%	1.08%	2.24%	150.18%	26.77%	-	-
Research & Development	5.4M	4.3M	5.51M	6.75M	8.12M	14.8M	8.19M	7.94M	3.31M	5.22M
R&D % of Revenue	0.62%	0.41%	1.01%	1.29%	2.53%	7.66%	245.45%	31.78%	-	-
Other Operating Expenses	0	0	-683K	-1.28M	-1.41M	-428.91K	-790.92K	-698.91K	-839.36K	-119.37K
Operating Income+	-7.11M	-5.71M	-7.59M	-9.06M	-10.54M	-18.59M	-13.1M	-14.24M	-7.7M	-9.44M
Operating Margin %	-0.81%	-0.55%	-1.4%	-1.73%	-3.28%	-9.63%	-392.76%	-56.96%	-	-
Operating Income Growth %	0.34%	0.2%	-0.33%	-0.19%	-0.16%	-0.76%	0.3%	-0.09%	0.46%	-0.23%
EBITDA+	-6.86M	-5.62M	-7.53M	-9.01M	-10.49M	-18.52M	-13.06M	-14.21M	-7.69M	-9.43M
EBITDA Margin %	-0.78%	-0.54%	-1.39%	-1.72%	-3.26%	-9.6%	-391.74%	-56.86%	-	-
EBITDA Growth %	0.35%	0.18%	-0.34%	-0.2%	-0.16%	-0.77%	0.29%	-0.09%	0.46%	-0.23%
D&A (Non-Cash Add-back)	247.46K	89.93K	68.56K	44.06K	54.45K	62.37K	34.16K	24.56K	6.55K	5.81K
EBIT	-7.11M	-5.71M	-7.59M	-9.06M	-10.11M	-18.51M	-12.51M	-14.13M	-7.67M	-9.46M
Net Interest Income+	-8.02K	2.22K	29.91K	158.57K	148.97K	-10.88K	-904.5K	-822.61K	-49.13K	213.97K
Interest Income	0	2.22K	29.91K	159.01K	148.97K	0	0	0	0	213.97K
Interest Expense	8.02K	0	0	0	0	10.88K	904.5K	822.61K	49.13K	0
Other Income/Expense	-1.21M	1.93M	29.91K	159.01K	574.75K	61.09K	-316.75K	-714.37K	-210.59K	763.81K
Pretax Income+	-8.32M	-3.78M	-7.56M	-8.9M	-9.97M	-18.53M	-13.42M	-14.95M	-7.91M	-8.68M
Pretax Margin %	-0.95%	-0.36%	-1.39%	-1.7%	-3.1%	-9.6%	-402.26%	-59.81%	-	-
Income Tax+	-489K	-530K	-417K	0	-610.68K	-836.89K	-864.74K	-1.15M	-1.77M	-409.11K
Effective Tax Rate %	0.94%	0.86%	0.94%	1%	0.94%	0.95%	0.94%	0.92%	0.78%	0.95%
Net Income+	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Net Margin %	-0.89%	-0.31%	-1.32%	-1.7%	-2.91%	-9.16%	-376.33%	-55.19%	-	-
Net Income Growth %	-0.17%	0.59%	-1.2%	-0.25%	-0.05%	-0.89%	0.29%	-0.1%	0.55%	-0.35%
Net Income (Continuing)	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-721.04	-321.60	-278.40	-162.09	-115.88	-154.45	-75.06	-76.89	-12.66	-4.98
EPS Growth %	-0.01%	0.55%	0.13%	0.42%	0.29%	-0.33%	0.51%	-0.02%	0.84%	0.61%
EPS (Basic)	-721.04	-223.20	-278.40	-162.09	-115.88	-154.45	-67.54	-76.96	-12.66	-4.98
Diluted Shares Outstanding	10.86K	14.93K	25.6K	54.91K	80.73K	114.53K	185.8K	179.46K	484.88K	1.66M
Basic Shares Outstanding	10.86K	14.51K	25.6K	54.91K	80.73K	114.53K	185.8K	179.29K	484.88K	1.66M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.15M	10.11M	9.42M	10.34M	7.49M	19.47M	26.57M	13.85M	9.51M	8.83M
Cash & Short-Term Investments	4.92M	8.77M	7.81M	8.98M	5.42M	18.68M	26.04M	13.36M	8.45M	7.82M
Cash Only	4.92M	8.77M	7.81M	8.98M	5.42M	18.68M	26.04M	13.36M	8.45M	7.82M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.99M	1.21M	1.34M	1.2M	1.46M	564.87K	242.72K	219.33K	195.15K	0
Days Sales Outstanding	82.64	42.15	90.25	83.69	166.05	106.8	2.66K	320.22	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	274.21K	866.01K	1.01M
Total Non-Current Assets+	236.1K	153.33K	133.85K	148.99K	282.04K	424.23K	300.41K	426.56K	290.01K	137.85K
Property, Plant & Equipment	47.37K	26.7K	37.16K	19.63K	161.5K	251.54K	128.38K	359.47K	241.76K	115.08K
Fixed Asset Turnover	185.11x	391.32x	146.17x	266.93x	19.91x	7.67x	0.26x	0.70x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	188.73K	126.63K	73.95K	46.86K	19.7K	23.25K	0	0	0	0
Long-Term Investments	0	0	0	0	0	73.14K	0	0	0	0
Other Non-Current Assets	0	0	22.73K	82.5K	100.83K	172.69K	172.03K	67.1K	48.24K	22.78K
Total Assets+	7.39M	10.27M	9.55M	10.49M	7.78M	19.89M	26.87M	14.28M	9.8M	8.97M
Asset Turnover	1.19x	1.02x	0.57x	0.50x	0.41x	0.10x	0.00x	0.02x	-	-
Asset Growth %	0.06%	0.39%	-0.07%	0.1%	-0.26%	1.56%	0.35%	-0.47%	-0.31%	-0.08%
Total Current Liabilities+	7.41M	2.87M	3.23M	4.21M	6.31M	6.08M	6.29M	16.52M	6.15M	4.85M
Accounts Payable	2.87M	1.71M	1.75M	2.13M	2.74M	2.13M	2.93M	3.87M	1.11M	667.9K
Days Payables Outstanding	152.18	73.92	148.51	168.78	279.88	426.92	1.47K	2.56K	546.59	2.04K
Short-Term Debt	292.72K	0	0	0	0	324.98K	0	9.9M	2.25M	1.37M
Deferred Revenue (Current)	298.68K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.43M	0	0	0	298.17K	0	302.94K	336.69K	2.42M	336.44K
Current Ratio	0.97x	3.52x	2.92x	2.46x	1.19x	3.20x	4.22x	0.84x	1.55x	1.82x
Quick Ratio	0.97x	3.52x	2.92x	2.46x	1.19x	3.20x	4.22x	0.84x	1.55x	1.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	6.15K	10.07M	9.86M	233.67K	1.12M	0
Long-Term Debt	0	0	0	0	0	9.95M	9.86M	0	1.01M	0
Capital Lease Obligations	0	0	0	0	6.15K	116.3K	0	233.63K	111.86K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	43	0	0
Total Liabilities	7.41M	2.87M	3.23M	4.21M	6.32M	16.15M	16.15M	16.75M	7.27M	4.85M
Total Debt+	292.72K	0	0	0	127.22K	10.51M	9.96M	10.24M	3.49M	1.48M
Net Debt	-4.63M	-8.77M	-7.81M	-8.98M	-5.29M	-8.17M	-16.08M	-3.12M	-4.95M	-6.33M
Debt / Equity	-	-	-	-	0.09x	2.81x	0.93x	-	1.39x	0.36x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-886.87x	-	-	-	-	-1708.00x	-14.48x	-17.31x	-156.69x	-
Total Equity+	-18.31K	7.4M	6.32M	6.28M	1.46M	3.74M	10.72M	-2.47M	2.52M	4.12M
Equity Growth %	0.88%	405.02%	-0.15%	-0.01%	-0.77%	1.57%	1.87%	-1.23%	2.02%	0.63%
Book Value per Share	-1.69	495.40	246.85	114.37	18.05	32.67	57.71	-13.77	5.20	2.48
Total Shareholders' Equity	-18.31K	7.4M	6.32M	6.28M	1.46M	3.74M	10.72M	-2.47M	2.52M	4.12M
Common Stock	31.27K	5.47K	8.73K	17.68K	21.75K	30.64K	2.86K	2.91K	10.38K	2.51K
Retained Earnings	-146.88M	-150.12M	-157.27M	-166.17M	-175.53M	-193.21M	-205.77M	-219.56M	-225.7M	-233.97M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-3.67K	-45.01K	-24.34K	41.94K	24.75K	22.24K	45.79K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.39M	-4.98M	-6.51M	-7.24M	-7.51M	-11.45M	-11.74M	-12.65M	-8.6M	-8.4M
Operating CF Margin %	-0.61%	-0.48%	-1.2%	-1.38%	-2.34%	-5.93%	-352%	-50.6%	-	-
Operating CF Growth %	-1.18%	0.07%	-0.31%	-0.11%	-0.04%	-0.53%	-0.02%	-0.08%	0.32%	0.02%
Net Income	-7.83M	-3.25M	-7.15M	-8.9M	-9.36M	-17.69M	-12.55M	-13.8M	-6.14M	-8.27M
Depreciation & Amortization	247.46K	89.93K	68.56K	44.06K	54.45K	62.37K	34.16K	24.56K	6.55K	5.81K
Stock-Based Compensation	886.69K	574.98K	489.79K	380.89K	376.34K	409.93K	361.56K	333.39K	370.18K	329.81K
Deferred Taxes	315.18K	-383.32K	0	0	-3.84K	0	-421.58K	0	0	0
Other Non-Cash Items	897.34K	-1.49M	5.92K	1.48K	282.35K	5.25M	185.72K	366.25K	597.4K	-124.26K
Working Capital Changes	98.25K	-529.88K	72.24K	1.23M	1.14M	509.31K	651.5K	425.11K	-3.44M	-348.41K
Change in Receivables	-1.19M	778.43K	280.53K	-275.46K	182.88K	815.06K	64.89K	23.76K	33.89K	219.9K
Change in Inventory	0	0	0	0	-1.97M	1.16M	-1.13M	0	0	0
Change in Payables	1.38M	-1.48M	382.71K	1.02M	1.97M	-1.16M	1.13M	396.65K	-2.69M	-492.61K
Cash from Investing+	-22.1K	-7.16K	-26.35K	-925	-24.71K	-7.15K	-11.79K	-13.07K	0	0
Capital Expenditures	-22.1K	-7.16K	-26.35K	-1.93K	-30.21K	-7.15K	-11.79K	-13.07K	0	0
CapEx % of Revenue	0%	0%	0%	0%	0.01%	0%	0.35%	0.05%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	1K	5.5K	0	0	0	0	0
Cash from Financing+	4.8M	8.84M	5.57M	8.42M	4.01M	24.68M	19.06M	76.82K	3.66M	7.76M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	965.68K	-850.66K	-672.36K	-251.89K	-130.2K	68.17K	-641.5K	-2.53K	-923.77K	3.32M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-5.41M	-4.99M	-6.54M	-7.25M	-7.54M	-11.46M	-11.75M	-12.66M	-8.6M	-8.4M
FCF Margin %	-0.62%	-0.48%	-1.2%	-1.38%	-2.34%	-5.94%	-352.36%	-50.65%	-	-
FCF Growth %	-1.15%	0.08%	-0.31%	-0.11%	-0.04%	-0.52%	-0.03%	-0.08%	0.32%	0.02%
FCF per Share	-497.97	-334.15	-255.34	-131.97	-93.39	-100.08	-63.25	-70.56	-17.74	-5.06
FCF Conversion (FCF/Net Income)	0.69x	1.54x	0.91x	0.81x	0.80x	0.65x	0.94x	0.92x	1.40x	1.02x
Interest Paid	0	0	0	0	0	34.41K	668.72K	857.41K	552.06K	227.74K
Taxes Paid	7.54K	5.03K	-5.08K	2.58K	11.13K	4.02K	7.73K	16.04K	20.73K	42.16K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-87.95%	-104.21%	-141.27%	-241.83%	-680.46%	-173.54%	-334.43%	-23803.12%	-248.97%
Gross Margin	21.51%	19.28%	20.66%	12.28%	-10.94%	5.68%	-2084.76%	-120.33%	-	-
Net Margin	-89.31%	-31.06%	-131.57%	-169.81%	-290.94%	-916.25%	-37632.97%	-5519.34%	-	-
Debt / Equity	-	-	-	-	0.09x	2.81x	0.93x	-	1.39x	0.36x
Interest Coverage	-886.87x	-	-	-	-	-1708.00x	-14.48x	-17.31x	-156.69x	-
FCF Conversion	0.69x	1.54x	0.91x	0.81x	0.80x	0.65x	0.94x	0.92x	1.40x	1.02x
Revenue Growth	24.49%	19.17%	-48.01%	-3.52%	-38.64%	-39.96%	-98.27%	649.6%	-100%	-

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Grant revenue	-	-	-	-	-	-	-	-	-	119.37K
Grant revenue Growth	-	-	-	-	-	-	-	-	-	-
CiVax	-	-	-	-	-	-	1.5M	1.5M	1.5M	-
CiVax Growth	-	-	-	-	-	-	-	0.00%	0.00%	-
Contract revenue	-	-	-	-	-	-	700K	600K	-	-
Contract revenue Growth	-	-	-	-	-	-	-	-14.29%	-	-
VaccinesBioDefenseMember	-	-	-	-	-	2.24M	-	-	-	-
VaccinesBioDefenseMember Growth	-	-	-	-	-	-	-	-	-	-
BioTherapeuticsMember	-	-	-	-	-	117.37K	-	-	-	-
BioTherapeuticsMember Growth	-	-	-	-	-	-	-	-	-	-
Vaccines Bio Defense	8.75M	10.45M	4.75M	4.16M	3.4M	-	-	-	-	-
Vaccines Bio Defense Growth	-	19.35%	-54.55%	-12.48%	-18.15%	-	-	-	-	-
Bio Therapeutics	13.97K	-	683.18K	1.08M	1.23M	-	-	-	-	-
Bio Therapeutics Growth	-	-	-	58.79%	13.19%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Soligenix, Inc. (SNGX) grew revenue by 0.0% over the past year. Growth has been modest.

Soligenix, Inc. (SNGX) reported a net loss of $10.6M for fiscal year 2024.

Dividend & Returns

Soligenix, Inc. (SNGX) has a return on equity (ROE) of -249.0%. Negative ROE indicates the company is unprofitable.

Soligenix, Inc. (SNGX) had negative free cash flow of $9.7M in fiscal year 2024, likely due to heavy capital investments.